Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Evolving treatment landscape for myeloma: ADCs

Rakesh Popat • 14 Dec 2020
ASH 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Lenalidomide MEDI2228 Pomalidomide
DREAMM-6

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the emergence of antibody-drug conjugates (ADC) as a new class of treatment for multiple myeloma, including belantamab mafodotin (belamaf) and belamaf-based combinations. There are also novel ADCs undergoing pre-clinical and early clinical trials, such as MEDI2228. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK

More from Rakesh Popat

2:06
The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma
Rakesh Popat • 16 Feb 2024
3:46
'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat • 16 Feb 2024
1:30
Selecting patients with myeloma for CAR-T: important clinical considerations
Rakesh Popat • 16 Feb 2024
1:14
The potential of CELMoDs for the treatment of R/R multiple myeloma
Rakesh Popat • 10 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals